What continuous biomanufacturing actually means in 2026

Continuous biomanufacturing is a bioprocessing paradigm in which biological materials — cells, media, intermediates, and purified product — flow without interruption through a series of integrated unit operations, rather than being processed in discrete, time-limited batch campaigns. In practical terms, this means a mammalian cell culture running in perfusion mode feeds directly into a continuous capture chromatography step, which in turn connects to polishing and formulation, all governed by real-time process analytical technology (PAT). The result is a manufacturing train that operates more like a refinery than a traditional pharmaceutical plant.

The distinction from fed-batch processing — the dominant mode in biopharmaceutical manufacturing for the past three decades — is fundamental. In a fed-batch process, a bioreactor is inoculated, nutrients are added over time, and the entire culture is harvested at the end of a fixed cycle, typically 10–14 days. Continuous processes, by contrast, maintain cells at a steady state by continuously removing spent media and product while replenishing fresh nutrients. This steady-state operation is the source of the technology’s most compelling advantages: higher volumetric productivity, smaller equipment requirements, and reduced variability between production runs.

By 2026, the concept of “end-to-end continuous” — integrating upstream perfusion culture with continuous downstream processing in a single, connected train — has moved from academic proof-of-concept to active clinical and commercial deployment at leading biopharmaceutical organisations. The technology is no longer a future aspiration; it is an active competitive differentiator.

The core technology pillars enabling end-to-end continuous processing

Four distinct technology pillars must converge for end-to-end continuous biomanufacturing to function reliably at commercial scale. Each pillar represents both an engineering challenge and a rich area of ongoing patent activity.

Perfusion cell culture (upstream)

Perfusion bioreactors retain cells using a cell retention device — most commonly an alternating tangential flow (ATF) filter or a tangential flow filtration (TFF) module — while continuously exchanging spent media for fresh nutrients. This maintains cell viability and density at a metabolic steady state, enabling continuous product secretion over weeks or months rather than the single-cycle harvests of fed-batch processes. Hollow-fibre bioreactors and single-use perfusion systems have expanded the technology’s accessibility to smaller manufacturers and clinical-stage organisations.

Continuous capture chromatography (downstream)

Periodic counter-current (PCC) chromatography and simulated moving bed (SMB) chromatography are the two principal approaches to continuous downstream capture. PCC systems use multiple columns cycling through load, wash, elute, and regeneration phases in an overlapping schedule, so that at least one column is always in the loading phase — eliminating the idle time that characterises conventional batch column chromatography. According to guidance published by the FDA, continuous chromatography can significantly improve resin utilisation and reduce buffer consumption compared with single-column batch operations.

Process analytical technology and digital control

Real-time monitoring is the connective tissue of a continuous process. In-line sensors measuring pH, dissolved oxygen, glucose, lactate, and product titre — combined with Raman spectroscopy and other spectroscopic tools — feed data to model-predictive control (MPC) systems that adjust process parameters automatically. This closed-loop control is essential for maintaining the steady-state conditions that underpin continuous manufacturing’s quality advantages. Standards from ISO and guidance from ICH (particularly ICH Q8, Q9, and Q10) provide the quality-by-design framework within which PAT systems are validated.

Innovation drivers: why the industry is accelerating the shift

The biopharmaceutical industry’s move toward continuous manufacturing is being propelled by converging commercial, scientific, and supply-chain pressures that have intensified since the early 2020s. Understanding these drivers is essential for R&D and IP leaders positioning their organisations’ technology portfolios.

Cost of goods pressure and facility economics

Biosimilar competition has compressed margins on established biologic products, while the cost of building new large-scale batch manufacturing facilities — often exceeding several hundred million dollars — has made continuous manufacturing’s promise of smaller footprint and lower capital expenditure increasingly attractive. A continuous process operating at steady state in a smaller bioreactor can match or exceed the output of a much larger batch facility, fundamentally changing the economics of new capacity investment.

Supply chain resilience post-pandemic

The COVID-19 pandemic exposed the fragility of batch-based biopharmaceutical supply chains, where a single failed batch can create months-long supply gaps. Continuous processes, with their inherent steady-state operation and real-time quality monitoring, offer a more resilient production model. The ability to run a manufacturing train for extended campaigns — weeks or months without interruption — reduces the frequency of high-risk batch transitions and changeover events.

Cell and gene therapy manufacturing complexity

Advanced therapy medicinal products (ATMPs) — including CAR-T cell therapies, viral vector-based gene therapies, and mRNA products — present manufacturing challenges that batch processes handle poorly at scale. The sensitivity of living cells to process variability, combined with the small lot sizes typical of personalised therapies, makes the precise, real-time-controlled environment of continuous processing particularly valuable. As the ATMP pipeline continues to expand, demand for continuous and semi-continuous manufacturing solutions in this segment is expected to grow.

“The ability to maintain a manufacturing train for weeks without interruption reduces the frequency of high-risk batch transitions — a compelling advantage for organisations managing complex biological molecules.”

Digital manufacturing and AI integration

The convergence of continuous bioprocessing with digital manufacturing — including machine learning-driven process optimisation, digital twins, and automated fault detection — is creating a new category of intelligent bioprocessing platforms. These systems use historical and real-time process data to predict and prevent deviations, further improving yield and quality consistency. Organisations at the forefront of this integration are filing patents that span both bioprocessing hardware and the software and AI methods that control it, creating multi-layered IP portfolios.

Regulatory landscape and quality-by-design alignment

Regulatory agencies have moved from cautious observation to active encouragement of continuous biomanufacturing, creating a more permissive environment for organisations making the transition. The FDA’s Emerging Technology Program, established to facilitate the adoption of novel manufacturing approaches, has engaged with numerous continuous manufacturing submissions and published guidance that explicitly supports continuous processing under a quality-by-design (QbD) framework.

The European Medicines Agency (EMA) has similarly developed guidance on continuous manufacturing, emphasising the importance of demonstrating process understanding and control strategy robustness. Both agencies align with the ICH Q13 guideline on continuous manufacturing of drug substances and drug products, which provides a harmonised international framework for regulatory submissions involving continuous processes. This harmonisation significantly reduces the regulatory complexity for organisations seeking multi-jurisdictional approvals.

A critical regulatory consideration for continuous biomanufacturing is the definition of a “batch” in a continuous context. Regulatory agencies have accepted time-defined and volume-defined batch concepts for continuous processes, allowing manufacturers to designate specific time intervals or output volumes as a batch for quality release purposes. This flexibility is essential for maintaining the commercial and supply-chain benefits of continuous operation while satisfying the batch-release requirements of pharmaceutical regulations.

Process validation in a continuous context also differs fundamentally from batch validation. Rather than validating discrete production runs, continuous process validation focuses on demonstrating that the process remains in a state of control over the intended duration of continuous operation — a concept sometimes referred to as “continued process verification” (CPV). Manufacturers must demonstrate that their PAT systems and control strategies can maintain product quality attributes within specification across the full range of operating conditions and durations.

IP strategy and patent landscape implications

The continuous biomanufacturing patent landscape is characterised by layered, multi-component IP portfolios that span hardware configurations, process methods, control algorithms, and analytical methods. Understanding the structure of this landscape is essential for organisations seeking to protect their own innovations, identify white spaces for new filing activity, and assess freedom-to-operate risks before committing to a continuous process platform.

Multi-component IP portfolio structure

A typical continuous biomanufacturing IP portfolio encompasses several distinct claim categories: apparatus claims covering bioreactor configurations and cell retention devices; process claims covering operating parameters, media compositions, and control strategies; method claims covering analytical techniques and sensor integration; and software claims covering control algorithms, digital twin implementations, and data analysis methods. Organisations that file across all these categories create a defensive perimeter that is significantly harder to design around than a portfolio concentrated in a single claim type.

White spaces and filing opportunities

Patent analysis of the continuous biomanufacturing landscape, accessible through platforms such as PatSnap, reveals several areas of relatively lower filing density that represent potential white spaces for new IP activity. These include the integration of continuous upstream and downstream operations in cell and gene therapy contexts, AI-driven predictive control systems for perfusion bioreactors, and novel cell retention device designs for high-viscosity or aggregation-prone cell lines. Organisations with R&D programmes in these areas may find relatively open terrain for building defensible patent positions.

Freedom-to-operate considerations

Organisations adopting commercially available continuous bioprocessing platforms — whether perfusion bioreactor systems from equipment suppliers or continuous chromatography systems from resin and hardware vendors — should conduct freedom-to-operate analysis covering both the equipment itself and the process methods they intend to use. In some cases, the use of a specific operating mode (such as a particular PCC cycling strategy) may be covered by method claims held by a competitor or equipment supplier, creating licensing obligations that are not apparent from the equipment purchase agreement alone. According to WIPO, method patents in bioprocessing are among the most frequently contested in pharmaceutical IP disputes, underscoring the importance of thorough FTO analysis before process lock-in.

Using patent intelligence to guide R&D investment

Beyond FTO, patent landscape analysis serves as a leading indicator of where the industry’s R&D investment is concentrated. A surge in filings around a specific sub-technology — such as hollow-fibre perfusion bioreactors or inline Raman spectroscopy for titre measurement — signals both competitive intensity and potential technology maturity. Conversely, areas with sparse recent filing activity may indicate either a white space or a technology that has been abandoned by the field. IP intelligence platforms such as PatSnap’s IP intelligence suite allow R&D and IP teams to query these patterns at scale using natural language, accelerating the strategic insight cycle from weeks to hours.